103 related articles for article (PubMed ID: 21283982)
1. Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.
De Sanctis A; Taillade L; Vignot S; Novello S; Conforti R; Spano JP; Scagliotti GV; Khayat D
Cancer; 2011 Jul; 117(14):3069-80. PubMed ID: 21283982
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy of non-small-cell lung carcinoma.
Tiwari D; Brodie SA; Brandes JC
Ther Adv Respir Dis; 2012 Feb; 6(1):41-56. PubMed ID: 21730004
[TBL] [Abstract][Full Text] [Related]
5. Recent developments in the chemotherapeutic options for nonsmall cell lung cancer.
Ibrahim MN; Abdullah Z; Martin MJ
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1397-410. PubMed ID: 17069525
[TBL] [Abstract][Full Text] [Related]
6. Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: analysis of early and late pulmonary morbidity.
Robert F; Childs HA; Spencer SA; Redden DT; Hawkins MM
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):136-47. PubMed ID: 10210553
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed for the treatment of non-small-cell lung cancer.
Manegold C; Schmid-Bindert G; Pilz LR
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for non-small cell lung cancer.
Toloza EM; D'Amico TA
Semin Thorac Cardiovasc Surg; 2005; 17(3):199-204. PubMed ID: 16253823
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
[TBL] [Abstract][Full Text] [Related]
10. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Rigas JR; Dragnev KH
Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
[TBL] [Abstract][Full Text] [Related]
11. New targets for non-small-cell lung cancer therapy.
Alvarez M; Roman E; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
[TBL] [Abstract][Full Text] [Related]
12. Sequencing chemotherapy, radiotherapy and surgery in combined modality treatment of stage III nonsmall cell lung cancer.
Maas KW; El Sharouni SY; Smit EF; Schramel FM
Curr Opin Pulm Med; 2007 Jul; 13(4):297-304. PubMed ID: 17534176
[TBL] [Abstract][Full Text] [Related]
13. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.
Gridelli C; Massarelli E; Maione P; Rossi A; Herbst RS; Onn A; Ciardiello F
Cancer; 2004 Oct; 101(8):1733-44. PubMed ID: 15386339
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
[TBL] [Abstract][Full Text] [Related]
15. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
Burris HA
Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
[TBL] [Abstract][Full Text] [Related]
16. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
[TBL] [Abstract][Full Text] [Related]
17. Molecular predictors of response to chemotherapy in non-small cell lung cancer.
Andrews J; Yeh P; Pao W; Horn L
Cancer J; 2011; 17(2):104-13. PubMed ID: 21427554
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
19. [The quality of life after chemotherapy in advanced non-small cell lung cancer patients].
SÅ‚owik-Gabryelska A; Szczepanik A; Kalicka A
Pol Merkur Lekarski; 1999 Jan; 6(31):18-22. PubMed ID: 10344148
[TBL] [Abstract][Full Text] [Related]
20. Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?
Booton R; Blackhall F; Kerr K
Thorax; 2011 Apr; 66(4):273-5. PubMed ID: 21345972
[No Abstract] [Full Text] [Related]
[Next] [New Search]